Single Nucleotide Polymorphism (SNP) Genotyping Market Size, Share & Forecast Report - 2026 to 2030

The global single nucleotide polymorphism genotyping market size is accounted to register a significant CAGR of over 11% during the forecast period 2025 to 2030. The rising prevalence of fatal incidences such as diabetes, cancer, and others is a major factor driving the market growth. The rising demand for genetic analysis in plants and animals is further expected to drive the market. Moreover, the presence of private and public funds programs in the field of genetics, reducing the cost of sequencing, the introduction of innovative technologies, and growing demand from clinical research. In addition, the technological advancement such as the increasing use of mass arrays systems and use of real-time and multiplex PCR is further expected to propel the market.

Industry Trends Shaping the Single Nucleotide Polymorphism (SNP) Genotyping Market:

The single nucleotide polymorphism (SNP) genotyping market is being shaped by the growing adoption of precision medicine and pharmacogenomics. With rising demand for personalized treatments, healthcare providers and researchers are increasingly using SNP genotyping to study genetic variations linked to drug response, disease susceptibility, and treatment outcomes. Advancements in high-throughput technologies, next-generation sequencing (NGS), and microarrays are enabling faster, more accurate, and cost-effective genotyping, expanding its use in clinical diagnostics as well as large-scale genomic research projects. The integration of SNP data into electronic health records is also enhancing the clinical utility of genetic information in patient care.

Another key trend is the expansion of SNP genotyping applications beyond healthcare into agriculture and biotechnology. SNP markers are being widely used in crop and livestock breeding programs to improve disease resistance, yield, and quality traits, fueling adoption in the agrigenomics sector. Additionally, the market is witnessing a surge in demand from academic research and biopharmaceutical companies conducting genome-wide association studies (GWAS). Strategic collaborations between technology providers, research institutions, and pharmaceutical companies are further accelerating innovation, while the rise of direct-to-consumer genetic testing services is broadening SNP genotyping’s reach to the general population.

Single Nucleotide Polymorphism (SNP) Genotyping Market Key Drivers:

The single nucleotide polymorphism (SNP) genotyping market is being driven by the rising demand for personalized medicine and pharmacogenomics. With increasing recognition that genetic variations influence drug response and disease risk, SNP genotyping is becoming a critical tool in tailoring treatments to individual patients. Its role in identifying biomarkers, predicting disease susceptibility, and improving therapeutic efficacy is fueling adoption in both clinical diagnostics and drug development. The rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions is further accelerating demand for SNP genotyping to support early diagnosis and targeted therapies.

Another key driving factor is the technological advancement and cost reduction in genomic analysis. High-throughput platforms, next-generation sequencing (NGS), and microarray technologies are enabling faster, more accurate, and affordable SNP detection. In addition, the increasing use of SNP markers in agriculture and livestock breeding to enhance yield, disease resistance, and quality traits is expanding the market beyond healthcare. Growing investments in genomic research, government-funded genome projects, and strategic collaborations between biotech firms and academic institutions are also fueling innovation and accessibility, making SNP genotyping a vital tool across healthcare, agriculture, and biotechnology sectors.

Single Nucleotide Polymorphism (SNP) Genotyping Market Opportunities:

The single nucleotide polymorphism (SNP) genotyping market offers major opportunities through the rising adoption of precision medicine and targeted therapies. As healthcare shifts toward individualized treatment plans, SNP genotyping provides crucial insights into genetic predispositions, drug efficacy, and adverse reactions. This creates strong demand in oncology, neurology, and cardiology, where patient-specific therapies are gaining prominence. Expanding applications in early disease detection and preventive healthcare also open new avenues, especially as consumer interest in direct-to-consumer genetic testing continues to grow. Emerging markets in Asia-Pacific and Latin America present additional opportunities due to increasing healthcare investments and growing awareness of genomic medicine.

Beyond healthcare, significant opportunities lie in agriculture and biotechnology. SNP markers are increasingly used in plant and livestock breeding programs to improve traits such as yield, nutritional value, and disease resistance. This is particularly important in addressing food security challenges and the growing demand for sustainable agriculture. Furthermore, advancements in genotyping platforms—such as portable, rapid, and cost-efficient technologies—will make SNP testing more accessible to smaller research institutions and clinics. Collaborations between technology providers, pharma companies, and agrigenomics firms also create pathways for innovation and market expansion, positioning SNP genotyping as a key enabler of both medical and agricultural breakthroughs.

Market Segment Insights:

The global single nucleotide polymorphism genotyping market is bifurcated into technology, application, and geography. On the basis of technology, the market is further segmented into SNP Genechips and Microarrays, TaqMan Assay, RFLP, SSCP, ARMS, and other SNP Genotyping Technologies. By application, the market is divided into animal genetics, plant improvement, diagnostic research, aquaculture, pharmaceuticals and pharmacogenomics, agricultural biotechnology, animal livestock and breeding, and others.

Global single nucleotide polymorphism genotyping market size and forecast was obtained by using “Bottom-up” and “Top-down” approaches. Extensive secondary research was conducted to understand the market insights and trends, followed by primary interviews to further validate the information sourced. The report provides both, qualitative and quantitative analyses of the market, the competitive landscape, and the preferred development strategies of key players which help to formulate competitive market strategies and make informed decisions.

Single Nucleotide Polymorphism (SNP) Genotyping Market Segmentation:

By Technology:

• SNP Genechips and Microarrays
• TaqMan Assay (Allelle-Specific Hybridization)
• SNP Genotyping based upon Pyrosequencing
• SN Plex based upon Applied Biosystems
• Sequenom Masarray MALDI-TOF
• RFLP (Restricted Fragment Length Polymorphism)
• SSCP (Single-Strand Conformation Polymorphism)
• ARMS (Amplication Refractory Mutation System)
• Other SNP Genotyping Technologies

By Application:

• Animal Genetics
• Plant Improvement
• Diagnostic Research
• Aquaculture
• Pharmaceuticals and Pharmacogenomics
• Agricultural Biotechnology
• Animal Livestock and Breeding
• Other SNP applications

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Geographic Coverage:

Geographically, the single nucleotide polymorphism genotyping market report comprises dedicated sections centering on the regional market revenue and trends. The market has been segmented on the basis of geographic regions into North America, Europe, Asia Pacific, and Rest of the World (RoW). The RoW segment consists of Latin America and the Middle East & Africa. The market has been extensively analyzed on the basis of various regional factors such as demographics, gross domestic product (GDP), inflation rate, acceptance, and others. SNP genotyping market estimates have also been provided for the historical years along with forecasts for the period from 2025 – 2030.

Single Nucleotide Polymorphism (SNP) Genotyping Market Competition Assessment:

Key players operating in the global single nucleotide polymorphism genotyping market are Sequenom, Inc., ThermoFisher Scientific, Life Technologies Corporation, PREMIER Biosoft, and Illumina, Inc. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

Key Companies:

• Sequenom, Inc
• ThermoFisher Scientific
• Life Technologies Corporation
• PREMIER Biosoft
• Illumina, Inc.
• Affymetrix, Inc.
• Douglas Scientific LLC
• Fluidigm
• GENEWIZ
• Eurofins Genomics

Key Questions Answered by Single Nucleotide Polymorphism Genotyping Market Report:

• Global SNP genotyping market forecasts from 2021-2027
• Regional SNP genotyping market forecasts from 2021-2027 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
• Country-level forecasts from 2021-2027 covering 15 major countries from the aforementioned regions
• SNP genotyping submarket forecasts from 2021-2027 covering the market by technology, by application, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis pertaining to market
• Analysis of the key factors driving and restraining the growth of the global, regional and country-level markets from 2021-2027
• Competitive Landscape and market positioning of top 10 players operating in the market